CEE 04421

Drug Profile

CEE 04421

Alternative Names: Analgesic tripeptide (CEE 04421) - CeNeS

Latest Information Update: 12 Sep 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute for Biological Standards and Controls; University of Sao Paulo
  • Developer BTG; CeNeS Pharmaceuticals
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation; Neuropathic pain; Postoperative pain

Most Recent Events

  • 12 Sep 2002 Discontinued - Preclinical for Inflammation in United Kingdom (PO)
  • 12 Sep 2002 Discontinued - Preclinical for Neuropathic pain in United Kingdom (PO)
  • 12 Sep 2002 Discontinued - Preclinical for Postoperative pain in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top